 Why Clinical Laboratories are at a Crossroads. Since 2022, more than 40% of independent labs have shut their doors, according to Lighthouse Lab Services’ recent analysis of CLIA and CMS data. Many of these closures stem from a lack of preparedness or reliance on outdated operating models. The result has been an industry shake-out that few are openly discussing. Yet within this disruption lies opportunity. As Jon Harol, Founder of Lighthouse Lab Services, explains, “The herd has been thinned. But the labs that adapt and prepare are the ones that continue to grow.” Consolidation means that while fewer labs remain, the demand for testing hasn’t disappeared, these sample volumes still need to be processed. For the organizations prepared to adapt, this moment represents a chance to capture more volume and expand their market position. Meeting Lab Owners Where They Are Lighthouse began in 2003 as a staffing and recruiting firm, created in response to widespread shortages of medical laboratory professionals. Over time, the company expanded its services based on client demand—adding part-time and full-time lab directors, PhD-level expertise for LDT validations and lab design, revenue cycle management, field service engineering, and even payer network access support. Harol describes the philosophy as simple: listen and respond. “We’ve always grown by asking what our clients need next and figuring out how to provide it,” he says. That approach has positioned Lighthouse as a multi-stop partner for more than 200 high-complexity CLIA labs across the country Tackling the Workforce Crisis  Despite industry shifts, staffing remains a perennial challenge. Lighthouse’s Wage & Morale Report underscores what many already know: labs are struggling to attract and retain qualified professionals. The difference, Harol notes, is in how leaders approach the problem. “The best labs play the long game. They invest in their culture because good culture attracts and retains talent.” Rather than relying solely on stopgap solutions like temporary workers, he encourages lab managers to focus on morale, team development, and flexibility. Even small changes, such as offering occasional remote work days for tasks like QC or paperwork, can have an outsized impact. “That kind of work-life balance often means more to employees than a pay bump,” Harol adds. Turning Compliance and Reimbursement Into Strengths For many lab managers, compliance oversight and reimbursement pressure feel like constant vulnerabilities. Harol sees it differently. With the right strategies, these areas can become competitive strengths. One key is being selective about sample volume. “We see labs chasing growth by bringing in as many samples as possible, but 40% of that work can end up unpaid,” he explains. Instead, successful labs ensure they’re targeting the right samples, those that drive revenue rather than drain resources. On the compliance side, Harol emphasizes that regulations, when taken seriously, can improve efficiency. Cutting corners often leads to wasted time and risk exposure. “Haste makes waste,” he says. Recent CLIA crackdowns on workforce credentialing are a case in point. While some push back at the added paperwork, Harol believes these checks ultimately strengthen labs and improve patient outcomes.  Busting Myths About Lab-Developed Tests Another area where Harol sees misunderstanding is in the perception of lab-developed tests (LDTs). “There’s no data showing that LDTs are driving bad results,” he points out. In fact, most errors occur in FDA-approved tests. Rather than vilifying LDTs, Harol argues, the real need is to modernize CLIA, which hasn’t been updated since 1988. With AI algorithms now producing lab results and digital samples flowing between laboratories, outdated regulations risk falling behind reality. “These are the areas we should focus on if we want to ensure quality testing for the future,” he says. Positioning Labs for the Future Looking ahead, Harol sees major changes on the horizon, not just for labs, but for healthcare overall. The shift from fee-for-service to value-based care will reward outcomes and preventative measures over volume alone. That puts labs in a powerful position. Despite accounting for just 2.6% of healthcare spend, laboratory testing informs 70% of medical decisions. “We are the best dollar you can spend in healthcare,” Harol says. “The labs that position themselves as partners in value-based care will thrive.” Final Takeaway Preparedness is no longer optional for clinical labs. Whether it’s building strong cultures, making strategic decisions about reimbursement, or modernizing compliance processes, resilience depends on a willingness to adapt. For Harol, the message is clear: “The labs that think long-term, invest in their people, and align with where healthcare is heading will not only survive—but grow stronger in the process.” This blog was compiled from key insights shared by Jon Harol, Founder of Lighthouse Lab Services, during his recent interview on Life Sciences Decoded. You can watch the full conversation here: https://youtu.be/BcPSO2hewgg
0 Comments
By Susan Najjar In life sciences, thought leadership carries a different weight than in other industries. Here, influence doesn’t just shape business decisions—it can affect funding priorities, regulatory frameworks, clinical practices, and ultimately, patient outcomes. That raises a critical question: how do you know if thought leadership is actually working? The Ultimate Measure of Success At its core, thought leadership in life sciences isn’t about personal brand, organizational visibility, or even influence alone. Its true measure is whether it advances science and improves health outcomes. Did your perspective help accelerate new approaches to rare disease trials? Did your work shape a regulatory framework that ensures patient safety? Did your collaboration bring diverse experts together to solve a complex challenge? Those are the outcomes that matter most. They are harder to measure than clicks or views, but infinitely more meaningful. The Long Game: Reputation and Trust Unlike marketing campaigns that can show immediate results, thought leadership is a long-term investment. It compounds over time. Each article, keynote, or collaborative paper adds to a reputation that can’t be built overnight. In life sciences especially, trust is the ultimate currency. Building that trust requires consistency, transparency, and a willingness to engage in dialogue—not just broadcast polished messages. The leaders who play the long game ultimately become the ones who guide how entire industry thinks about science, regulation, and innovation. Moving Beyond Vanity Metrics Too often, success is measured through digital vanity metrics—likes, views, or impressions. While those numbers show visibility, they don’t capture credibility or real-world impact. In life sciences, thought leadership must be measured by deeper indicators that reflect trust, relevance, and tangible outcomes. It’s tempting to equate popularity with impact. A LinkedIn post that racks up 10,000 impressions may feel like a win, but unless it sparks meaningful engagement or influences decisions, its value is limited. True thought leadership is less about being seen everywhere and more about being heard in the right places by the right people.  Metrics That Matter in Life Sciences
So, what does meaningful measurement look like? Here are the indicators that signal thought leadership is creating influence that lasts: 1. Invitations to Speak When your perspective is valued, others want you on their stages—whether at academic conferences, policy panels, industry roundtables, or internal leadership sessions. Speaking invitations show that peers recognize your authority and want your voice in critical conversations. 2. Policy and Regulatory Influence Perhaps the most powerful marker of thought leadership in life sciences is shaping policy. If your ideas are referenced in regulatory guidance, cited in public consultations, or included in industry position papers, it means your voice is advancing standards that govern how science is practiced and applied. 3. Citations and Mentions Whether in journals, industry reports, or digital forums, citations signal credibility. When others reference your work, it demonstrates that your insights are viewed as trusted resources within the field. 4. Collaborations and Partnerships Thought leadership often opens doors to new research collaborations, grant opportunities, and cross-sector partnerships. Influence becomes impact when it attracts others who want to innovate with you. 5. Recruitment and Retention Strong thought leadership makes organizations talent magnets. Top scientists and professionals want to work with leaders who are shaping their field. It also strengthens retention by fostering pride in being part of a forward-looking team. Final Thoughts Measuring thought leadership in life sciences means asking tougher questions than “how many people saw this?” It’s about assessing whether your work earned trust, opened doors, and contributed to progress that ultimately benefits patients and society. In a field where credibility is everything, the path from influence to impact is measured not by visibility, but by the legacy you leave in advancing science and improving lives.  By Meghan O'Sullivan Science can fail in the lab - but more often if fails in the story. Great products, ideas, and innovations don’t fail because they don’t work. They fail because no one understands why they matter. That usually comes down to one thing: poor storytelling. Without a clear, compelling narrative, science stalls before it starts which leads to no funding, no adoption, no impact. You can have the most advanced platform, the most precise assay, or the most cutting-edge robotics, but if your story doesn’t cut through the noise, your breakthrough will disappear in a sea of “solutions” that all sound the same. Innovation rarely dies with a bang. More often, it dies quietly, in the silence that follows a story never told, or told badly. Here are 5 of the most common storytelling mistakes in science and how to avoid them.
 Create A Winning Story Great products fail every day, not because they lack features, but because they lack a story that resonates. To win, your solution must be clearly connected to your customer’s problem. If you want your product to stand out, you need to:
In the end, your product is your story. If you don’t own it, get it right, and tell it often, the market will only hear silence. At Life Sciences Decoded, we help life science leaders turn their story into an engine for trust and visibility. One on-camera interview becomes a full package of assets — clips, blogs, and distribution through leading publications. Start simple: book a single interview, and see how far your story can travel.  An interview with Eric Mayton, CEO of Cerillo | As featured on the Life Sciences Decoded podcast
Scientific research is moving faster than ever, and so is the need for tools that match that pace. On a recent episode of Life Sciences Decoded, we sat down with Eric Mayton, CEO of Cerillo, a company that's making waves with its innovative platform for microbial research and beyond. Cerillo is a bio-tools company based in Charlottesville, Virginia, spun out of the University of Virginia. While small in size, just ten employees, Cerillo’s reach spans nearly 30 countries, thanks to a nimble business model, powerful partnerships, and a bold mission: to make research more reproducible, scalable, and flexible. What’s Broken in Scientific Research? According to Mayton, one of the major pain points in scientific research is the inability to study real-world microbial interactions with accuracy and speed. “Microbes don’t live in isolation, but we’ve been studying them as if they do,” he says. “It’s hard to control the thousands of variables that affect microbial behavior, and wet lab validation has been too expensive, too slow, and too complex.” Cerillo’s solution? Miniaturized hardware, intuitive software, and a novel consumable that together create a platform for real-time, high-throughput experimentation, without the overhead of traditional systems. The Duet System: Rethinking Microbial Interactions One of Cerillo’s most innovative offerings is the Duet system, a plastic consumable that lets scientists study microbial interplay in a shared environment while keeping organisms physically separate using a semipermeable membrane. It’s a deceptively simple innovation with game-changing impact. Mayton shares the story of a hospital-affiliated researcher investigating antibiotic-resistant syphilis cases post-COVID. Using just one Duet tray, the researcher tested various combinations of microbes and pinpointed the single species responsible for resistance, something that would have taken weeks using conventional tools. That discovery is now guiding more targeted therapies and reducing the unnecessary use of broad-spectrum antibiotics. From Yogurt to Bioreactors The use cases don’t stop at healthcare. “We have customers using the Duet for biofuel development, alcoholic fermentation, and even probiotic research in yogurt manufacturing,” says Mayton. “Our platform meets scientists where they are, whether they’re at the bench or scaling up for production.” The key to this flexibility? Everything fits in a briefcase. Cerillo’s field kits are shipped globally, enabling partners to demonstrate, deploy, and support without an army of application specialists. Most users can go from unboxing to collecting data in under ten minutes. Punching Above Their Weight So how does a 10-person company compete in a space dominated by giants? Agility. “We’re able to take real feedback from customers and rapidly iterate,” says Mayton. “It’s not about the size of your R&D team—it’s how fast you can get the right tools into the right hands.” Cerillo also emphasizes self-service and support. Their online Help Center, born from support ticket trends and FAQ analysis, ensures users can find what they need quickly. “It’s about empowering scientists to move at the speed of their ideas,” Mayton explains. AI in the Lab: Hype or Help? Mayton acknowledges that AI is everywhere, but it’s important to understand how and where it fits. “Large language models are great for speeding up documentation, protocol generation, and customer support,” he notes, “but they can’t make scientific decisions.” Instead, Cerillo is exploring other AI models, like Bayesian optimization, for real-time experimental design and autonomous science. Myth-Busting the Bio-Tools Market As we wrapped up, Mayton addressed a common myth in the scientific tools space: “Just because you’ve built a cool product doesn’t mean people will adopt it. You have to connect the dots, show the customer how it fits into their workflow and why it matters.” Cerillo’s success lies not just in what they’ve built, but in how well they’ve listened, adapted, and supported their users. From Bench to Breakthrough Cerillo’s story is a compelling reminder that innovation doesn’t require a sprawling team or massive infrastructure. Sometimes, it just takes a smart system in a suitcase—and the will to meet scientists where they are. The Big Chill moment that made me rethink how we talk about science By Meghan O'Sullivan The other night The Big Chill was on, so I did my usual routine: hit “info” to check the year and see how old the actors were back then. And then I saw it. The movie description. Either the work of a well meaning intern, or more likely AI. “A group of old college friends sit around, listen to records, and talk.” I called my husband into the living room and we had a good laugh. “Technically accurate. Emotionally bankrupt.” I said with a grin. You see, the description failed to mention that it’s about a group of college friends who reunite after 15 years for the funeral of one of their friends, who committed suicide. Or that the film explores themes of friendship, loss, disillusionment, and the passage of time. That’s the story. Strip it down and you lose the soul of it. It made me wonder; is storytelling lost on the next generation? And then I realized that maybe it’s not just a generational issue. Maybe it’s that AI is forcing us to undersell ourselves. We bury the why in a sea of how.
The result? A lost opportunity to connect, not just with customers, but with patients, partners, and investors. Because no matter how brilliant your science is, if people don’t feel something, they won’t remember it.  So Why Are Life Science Companies So Reluctant to Embrace Storytelling? Here are the five most common reasons life science companies have given me over the years, for not focusing on their story. - "It feels forced.” - “Our CEO is really low-key." - “What we do isn’t that exciting.” - “It’s too complicated to explain.” - “Only a small audience really gets what we do.” Enough with the excuses. I’m calling them out one by one! Excuse #1: “It feels forced.”
The Truth: Then you’re telling the wrong story or telling it the wrong way. A good story never feels forced. It feels real. When you focus on the real impact of your work on patients, researchers, or even on the planet it becomes natural to tell. You don’t need to manufacture drama; you need to reveal the humanity behind the science. Start with the people side of it. Example: Imagine your company builds robotic automation for high-throughput screening. On the surface, it’s about precision, speed, and efficiency. But behind the hardware is something far more human. Because of that automation, a diagnostic lab was able to process thousands more samples each week, cutting turnaround time from days to hours. That meant a newborn with a rare metabolic disorder got the right treatment before symptoms even appeared. It meant a father with aggressive cancer started therapy while it could still make a difference. The story isn’t about robotics. It’s about what happens because of robotics. Faster answers. Earlier interventions. Lives changed. Lives saved. A title for this story could be: The Heartbeat Behind the Hardware. Excuse #2: “Our CEO is very low key.” The Truth: You don’t need a flashy spokesperson to tell a powerful story. In fact, some of the most compelling narratives come from quiet leaders who speak with conviction, not charisma. The key is to meet them where they are. Let them speak in their own voice. Maybe it’s a reflective quote on why they started the company, or a brief anecdote that anchors the mission. And if they’d rather stay behind the scenes? No problem. Let the science team, a patient advocate, a partner, or even a customer be the voice. Storytelling isn’t about spotlighting the loudest person it’s about illuminating the purpose behind your work. Authenticity beats volume every time. Excuse #3: "What we do isn’t really that exciting.” The Truth: Not exciting? You’re developing life-saving diagnostics, pushing the frontiers of biotech, decoding disease, or engineering the next generation of therapies. If that’s not exciting, what is? The challenge is not what you do, it’s how you talk about it. Example: Let’s say your company develops quality control software for clinical labs. It runs quietly in the background, flagging inconsistencies and ensuring that instruments are working properly. Not exactly headline material, right? But now imagine this: because of that software, a false negative was caught before a patient was mistakenly told they were cancer-free. That tiny flag in the system prevented a life-altering delay in treatment. Suddenly, what sounded routine is now a story about trust, accuracy, and accountability in moments that matter. The work may be invisible, but its impact isn’t. You don’t need to embellish. You just need to connect the dots between what you do and why it matters. 4. “It’s too complicated to explain.” The Truth: Yes, science is complex, and that’s a good thing. But complexity doesn’t mean your story has to be confusing. You’re not dumbing it down, you’re distilling it. Think of it like using a microscope: you don’t show your audience the entire slide, you zoom in on one meaningful field of view that tells the story. Lead with the why - the problem you’re solving or the outcome you’re enabling-then reveal just enough of the how to build trust and curiosity. Ditch the acronyms and layered mechanisms in your first breath. Start with impact. Example: Let’s say you’re a company using AI to optimize antibody discovery. The algorithm itself is complex, and the team gets lost in descriptors like “iterative active learning loops” and “sequence space mapping.” Now imagine reframing it this way: “Every day without an effective antibody means another patient with no treatment. Our platform learns from every failed experiment, so we get to the right therapeutic candidates in a fraction of the time.” You’ve just made a machine learning platform about human urgency. You didn’t ignore the science, you made it serve the story. The truth is, every company has a story worth telling. Especially in life sciences, where the stakes are high and the breakthroughs are real. Excuse #5: “Only a small audience understands what we do.” The Truth: Niche audiences tend to be highly engaged, especially when you speak their language and reflect their challenges. But don’t stop there. A well-told story can ripple far beyond the technical crowd. Investors, collaborators, future hires, and even regulatory reviewers pay attention when the narrative is clear and compelling. Good storytelling doesn’t dilute your science, it amplifies your mission. Example: Suppose you're a synthetic biology startup engineering microbial consortia for soil remediation. It sounds esoteric, and sure, your core audience might be environmental scientists and industrial biotech specialists. But when you explain it like this: “We’re programming microbes to clean toxic soil so that abandoned industrial sites can become places where kids play again,” You’ve suddenly opened the door to policymakers, grant funders, and impact investors. You didn’t lose your niche audience. And you expanded your reach. Conclusion: Bring Back the Story! We don’t need to abandon data. We just need to embed it in something human. Storytelling isn’t fluff. It’s not extra. It’s how we make meaning out of the work we do. It’s how we get others to care. To fund us. To join us. To believe in us. So, if you're sitting on a good story instead of making it technical and data driven – Stop! Find the life in your life sciences story. Or risk having someone sum it all up with: “A group of scientists just sit around, run assays, and talk.” By Susan Najjar RNA therapies have surged into the spotlight in recent years, thanks to their role in the rapid development of COVID-19 vaccines. But according to Nigel Theobald, CEO of N4 Pharma, the real story is only just beginning. In a recent interview with Life Sciences Decoded, Nigel broke down the fundamentals of RNA therapeutics and explained why the next major leap in this field depends not on the RNA itself—but on how it's delivered. What Are RNA Therapeutics, and Why Do They Matter? Nigel offers a down-to-earth explanation: “RNA, along with DNA, are nucleic acids—core components of all human life. RNA acts as a messenger, translating DNA's genetic instructions into proteins that the body needs to function.” But in diseases like cancer, inflammatory bowel disease (IBD), or viral infections, the body may produce too much or too little of a critical protein. RNA therapies aim to correct that imbalance. They either:
The potential? Tremendous. RNA can target previously "undruggable" diseases, offers a faster path to discovery than traditional small molecules or antibodies, and can even be tailored for personalized medicine. The Catch: Delivery is Everything Despite the promise, one glaring challenge remains: getting RNA into the right cells safely and effectively. “RNA is fragile,” Nigel explains. “The body immediately tries to break it down. Even if you protect it, you still face barriers like the cell membrane. Both RNA and the cell surface carry negative charges—they repel each other. Most delivery systems only succeed by overwhelming the body with a large dose, hoping a small fraction gets through.” And even if RNA enters a cell, it can get stuck in the endosome and never reach the cytoplasm where it’s needed. Add to that the fact that today’s systems tend to deliver RNA indiscriminately across the body—most ending up in the liver—and you have a delivery bottleneck limiting the potential of RNA therapies. Enter Nuvec®: A Novel Silica-Based Delivery System To solve this, N4 Pharma developed Nuvec®, a silica nanoparticle with a unique “spiky” structure that mimics grass burrs sticking to your socks. This structure:
“Existing systems like lipids or viral vectors can only deliver one thing at a time, and they’re expensive and complex to make,” Nigel explains. “Our silica particles are easy to manufacture, scalable, and low-cost. We’re not just solving delivery—we’re expanding what delivery can do.” From Science to Application: A New Hope for IBD N4 Pharma’s first clinical candidate--N4-101—is being developed for ulcerative colitis, a serious form of inflammatory bowel disease. What makes it stand out?
In preclinical studies, N4-101 demonstrated:
All with a capsule designed to release at the ideal pH level—directly in the upper GI tract.  A Future Beyond Injections
So, are injections the only route for RNA therapies? “Not anymore,” Nigel says. “They only dominate because of today’s limitations. But with novel delivery systems like Nuvec, we’re proving that oral and even topical applications are possible.” And that opens the door to a future where RNA therapies could be taken as easily as antibiotics—targeting everything from rare genetic diseases to common chronic conditions. The Bottom Line: RNA Therapies Need Better Delivery to Realize Their Promise The science behind RNA is sound. The potential is vast. But as Nigel puts it, “RNA therapeutics are only as effective as the systems that deliver them.” N4 Pharma’s Nuvec system is tackling this head-on—with a delivery platform that is protective, scalable, customizable, and most importantly, patient-friendly. As the industry shifts from promise to practical application, innovations in delivery may well be the key that unlocks RNA’s full therapeutic power. By Susan Najjar
In our previous post, we examined why thought leadership matters in life sciences: it builds trust, attracts top talent, drives engagement, and translates complex science into actionable insight. Now comes the practical question: How do you establish yourself as a credible thought leader in a field defined by complexity, regulation, and rapid innovation? Here’s a strategic framework. 1. Narrow Your Focus to Increase Your Impact Effective thought leaders don’t try to cover every development across the sector. They specialize in high-impact areas where their expertise can drive real dialogue and change. Focus your lens:
Ask yourself: What questions aren't being addressed in my field? What assumptions need challenging? Great thought leadership often starts by addressing the blind spots. 2. Share Ideas at the Speed of Innovation Publishing in peer-reviewed journals is essential, but it’s not enough. Thought leaders today engage dynamically across platforms that move faster than traditional academic channels. Consider:
3. Lead with Framing, Not Just Facts You’re not just explaining mRNA stability. You’re articulating why it matters for global vaccine equity, biomanufacturing, or regulatory policy. Thought leadership positions the why now, not just the what is. Strong framing examples:
4. Make the Technical Tangible Even among experts, clarity accelerates trust. Make scientific insights easier to contextualize by linking them to outcomes:
5. Build Dialogue, Not a Monologue Thought leadership is relational. It involves amplifying others, not just broadcasting your own message.
6. Identify Gaps—Then Lead Into Them The most compelling thought leadership often emerges where others hesitate:
7. Prioritize Substance Over Visibility True thought leadership is not self-promotion. It’s about elevating your field. That means:
It’s less about being seen everywhere and more about showing up where it counts, with perspective that matters Final Takeaway: Teach, Challenge, and Connect You’re not just advancing your company or your research, you’re shaping how your field thinks. And in life sciences, that influence carries real-world impact.
By Susan Najjar
The term thought leadership is often met with skepticism in life sciences. It's used so frequently that many professionals dismiss it altogether. But when applied with substance, thought leadership becomes a valuable tool, one that helps organizations articulate their vision, build credibility, and influence the broader scientific conversation. In a highly technical and risk-aware industry, how you communicate can matter as much as what you’re building. Companies that lead the conversation gain visibility, trust, and traction. Those that stay silent risk being overlooked. 1. Science No Longer Sells Itself A breakthrough discovery isn’t enough on its own. You might have identified a new biomarker or developed a novel AI model, but without a clear and compelling story, it may not get noticed. 2. Influence Builds Trust Life sciences is a sector defined by smart skepticism. Partners, buyers, clinicians, and investors are cautious by design. They evaluate not just the strength of your vision and pipeline, but also the depth of your understanding and your ability to communicate with clarity. 3. Thought Leaders Set the Narrative Innovation is constant in life sciences. From gene editing to microbiome research, the pace is staggering. In these rapidly evolving areas, the most influential voices are often those who can distill complexity and shape discussion. Effective thought leadership allows you to guide how your field is understood. You become the reference point. Your perspectives, frameworks, and questions set the tone for others. 4. It Attracts the Right Talent People want to work for companies that stand for something. Skilled scientists, engineers, and professionals seek environments that offer more than tasks. They want purpose, clarity, and leadership. When your leadership team publishes meaningful insights or shares perspectives on industry challenges, you signal that your organization is thoughtful, forward-looking, and worth joining. For high-performing candidates, this matters. 5. It Scales and Delivers Lasting Value Unlike drug development or clinical trials, thought leadership doesn't require regulatory review or years of lead time. It scales easily across blogs, webinars, LinkedIn posts, podcasts, newsletters, and media interviews. Done well, it builds brand equity, credibility, and engagement. It’s one of the few strategic tools with immediate visibility and long-term value. 6. Video Accelerates Visibility and Trust Thought leadership is most effective when it’s seen and heard, not just read. In a digital-first ecosystem, video has become the most powerful way to communicate expertise at scale. Scientific leaders who appear in interviews, panel discussions, or short-form videos build a stronger, faster connection with their audience. How to Communicate with Clarity Life sciences content can easily become dense and technical. To stand out:
Final Thoughts In an industry where nearly everyone claims to be “first” or “next-generation,” how you talk about your work can differentiate you as much as the work itself. Thought leadership is not a trend. It is a strategic tool. It turns science into story, knowledge into influence, and perspective into partnerships. And today, the most effective thought leaders aren't just publishing articles, they’re showing up on screen. That’s where visibility starts, and where real impact begins. This article reviews how thought leadership builds trust, drives engagement, attracts talent, and turns your science into story. Stay tuned for our next blog that discusses practical steps you can take to standout as thought leader in life sciences. In biopharma, time isn’t just money, it’s product, safety, and reputation on the line. Yet for decades, manufacturers have been operating in the dark, waiting five to twenty-eight days for microbial test results that determine whether a batch is safe or contaminated. That delay can cost companies tens to hundreds of millions of dollars per incident. On a recent episode of Life Sciences Decoded, I sat down with Dr. Jack Regan, CEO, CTO, and Co-Founder of MantaBio, to discuss how his company is tackling this massive bottleneck with automation, PCR-based detection, and real-world insights. The Cost of Flying Blind In the biopharma world, manufacturing happens in warm, nutrient-rich bioreactors which are perfect not just for growing therapeutic biologics like Keytruda or Humira, but also for harboring microbial contamination. “If you're waiting 28 days to detect contamination, you're flying blind,” Regan explained. “You could be losing a $20 million batch or worse, contaminating multiple lines from a single source.” Contamination risks extend beyond product loss. A single event can lead to:
MantaBio’s 2-Hour Solution Enter MantaBio, a company designing a fully automated, PCR-based microbial detection system called MantaVision, purpose-built for the demands of biomanufacturing. “We’re not adapting clinical tech into biopharma,” Regan noted. “We’re building this from the ground up for industrial-scale testing.” Unlike traditional methods based on century-old cell culture, which involve plating samples and waiting for colonies to grow, MantaBio delivers results in just two hours. That speed allows manufacturers to detect contamination early, intervene faster, and avoid unnecessary product loss.  Designed for Manufacturing Environments
A major advantage of MantaBio’s approach? It eliminates one of the biggest risks in microbial detection: sub-sampling errors. Traditional methods often rely on testing small sample volumes, which can easily miss low-level contamination. MantaVision is engineered to process larger volumes, increasing the statistical likelihood of catching contaminants before they become costly. And it’s not just about volume, it’s also about usability. The system is:
As Jack Regan puts it: “It’s like the Keurig of molecular biology. Pop in your sample, and out comes a genetic result you can trust.” A Heart Monitor for Your Bioreactor What makes MantaVision more than just a faster test is how it integrates across the entire manufacturing process. The MantaVision is intentionally modular by design, so that customers can easily scale up to meet their testing needs. Most companies would like to deploy 4-5 systems per line, testing at multiple stages, fermentation, harvest, purification, and final product. It’s like having a continuous heart monitor for the bioreactor. “If something spikes, you know early,” Regan explained. “You can pause, isolate, and resolve the issue before it snowballs.” That kind of real-time insight doesn’t just save product. It gives manufacturers a clear path to more reliable operations, fewer recalls, and shorter time to market. Not Just Faster — Smarter Beyond rapid detection, MantaBio’s platform also supports speciation which is the ability to identify which microbe is present, not just whether contamination occurred. That insight helps teams perform root-cause analysis and prevent recurrence. “The goal isn’t just speed,” Regan said. “It’s confidence in the results, in the product, and in the decisions you make next.” What’s Next for MantaBio? While the system is still in development, MantaBio is already working closely with leading biomanufacturers to ensure the platform meets real-world needs. The team is conducting rigorous validation, refining usability, and aligning with evolving regulatory expectations. “There’s currently no dominant player delivering this kind of molecular testing in biopharma,” Regan said. “We’re building the system the industry has been asking for.” And that could change everything. Want to learn more? Visit mantabio.com or follow MantaBio on LinkedIn for updates. Listen to the full conversation on Life Sciences Decoded |
Authors
Meghan O'Sullivan
Susan Najjar
|
